Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orient Pharma CoROCO:4166 +0.82%70 Cash Ratio is 3.39 as of Jun. 2026, which is 637% above its 10-year median of 0.46. GuruFocus rates ROCO:4166 with a GF Score™ of 70/100 and a GF Value™ of NT$41.31 (Significantly Undervalued). Among 950 Drug Manufacturers companies, Orient Pharma Co ranks better than 87.26% on this metric.
Orient Pharma Co (ROCO:4166) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Orient Pharma Co Cash Ratio Related Terms
Orient Pharma Co Cash Ratio Historical Data
* Premium members only.
The historical data trend for Orient Pharma Co's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orient Pharma Co's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orient Pharma Co Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orient Pharma Co's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Orient Pharma Co's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orient Pharma Co (ROCO:4166) has a Cash Ratio of 3.39 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Orient Pharma Co and its competitors. This is 637% above median its historical median of 0.46. Over the past decade, Orient Pharma Co's Cash Ratio has ranged from 0.13 to 4.21. According to the industry distribution chart, Orient Pharma Co ranks #121 out of 950 companies in the Drug Manufacturers industry, placing it in the top 12.7%.
Is Orient Pharma Co's Cash Ratio too high?
Orient Pharma Co's current Cash Ratio of 3.39 is 637% above median its 10-year median of 0.46. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 4.21. The Drug Manufacturers industry median Cash Ratio is 0.58. Orient Pharma Co's value of 3.39 is 484.5% above this industry median. Based on the distribution chart, Orient Pharma Co ranks #121 out of 950 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Orient Pharma Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orient Pharma Co's Cash Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Orient Pharma Co ranks #121 out of 950 companies for Cash Ratio. This places Orient Pharma Co in the top 13% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.58. Orient Pharma Co's value of 3.39 is 484.5% above this benchmark. Historically, Orient Pharma Co's own Cash Ratio has ranged from 0.13 to 4.21 over the past decade. While the company's 10-year median is 0.46 vs. the industry median of 0.58, Orient Pharma Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.58, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orient Pharma Co's current Cash Ratio of 3.39 is 484.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Orient Pharma Co and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orient Pharma Co's current Cash Ratio is 3.39, which is 637% above median its own 10-year median of 0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Pharma Co (ROCO:4166) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$41.31, compared to a current price of NT$24.70 — trading 40.2% below its estimated fair value. The current Cash Ratio is 3.39, which is 637% above median its 10-year median of 0.46 and 484.5% above the Drug Manufacturers industry median of 0.58. Orient Pharma Co's overall GF Score™ is 70/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Orient Pharma Co (ROCO:4166), the current Cash Ratio is 3.39 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orient Pharma Co (ROCO:4166) Overvalued in 2026?
Based on GuruFocus' analysis, Orient Pharma Co stock appears to be undervalued.
The current stock price of NT$24.70 is trading 40.2% below its estimated GF Value™ of NT$41.31.
GuruFocus considers Orient Pharma Co to be Significantly Undervalued.
Key valuation signals for ROCO:4166:
Cash Ratio: 3.39 (637% above median its 10-year median of 0.46)
GF Value™: NT$41.31 vs. price of NT$24.70 (40.2% below fair value)
Industry Position: 484.5% above the Drug Manufacturers median (#121 of 950)
No single metric tells the full story. See the ROCO:4166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The Company mainly engages in the manufacturing, wholesale, and retail of western medicine and medical devices, as well as international trade. The company has two operating segments-Taiwan business segment- mainly engaged in developing the Taiwan pharmaceutical market and conducting related business activities and the other segment is Overseas business segment -mainly engaged in developing potential overseas pharmaceutical markets. Company's products include Cardiovascular drugs and Psychotropic drugs. The Group mainly operates in four regions: Taiwan, the United States, the Philippines, and China generating key revenue from Taiwan.
70GF Score
Get the complete analysis for ROCO:4166
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4166 has been successfully added to your 
